This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ETX2514

Entasis Therapeutics

Drug Names(s): ETX 2514, ETX-2514

Description: ETX2514 is a broad and potent inhibitor of class A, C, and D beta-lactamases. Entasis Therapeutics is developing the combination of sulbactam and ETX2514 for the treatment of severe Acinetobacter baumannii infections.

Sulbactam is a beta-lactam antimicrobial active against A. baumannii, but beta-lactamase-mediated resistance to sulbactam is now widespread. In preclinical studies, ETX2514 restores sulbactam’s antimicrobial activity.


ETX2514 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug